EU regulators dismiss soy heart health claim
This article was originally published in The Tan Sheet
Executive Summary
The European Food Safety Authority concludes that a cause and effect relationship is not established between the consumption of soy protein and lower levels of low-density lipoprotein cholesterol, which lowers the risk of coronary heart disease. Though petitioners submitted 40 studies, the regulatory authority rejected most because they did not test soy protein but soy protein isolate or soy foods containing other substances that have a proven effect on heart health. The petitioners submitted four additional meta-analyses, all of which EFSA said failed to show a relationship between the consumption of soy protein and lower levels of LDL. The soy heart health claim also is under fire in the U.S., where nutrition groups submitted a 2008 citizen petition to FDA to have the health claim overturned and the American Heart Association recommended the claim be revoked (1"The Tan Sheet" Sept. 1, 2008)
You may also be interested in...
Soy Protein Under Fire, But Experts, Industry Confident In Heart Health Claim
Nutrition experts say a citizen petition requesting FDA revoke a health claim linking soy protein to heart health benefits weakens its own argument by citing data selectively and in error
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.